Standard

CAR T-cell therapy : Balance of efficacy and safety. / Kulemzin, S. V.; Kuznetsova, V. V.; Mamonkin, M. et al.

In: Molekuliarnaia biologiia, Vol. 51, No. 2, 26.05.2017, p. 274-287.

Research output: Contribution to journal › Review article › peer-review

Harvard

Kulemzin, SV, Kuznetsova, VV, Mamonkin, M, Taranin, AV & Gorchakov, AA 2017, 'CAR T-cell therapy: Balance of efficacy and safety', Molekuliarnaia biologiia, vol. 51, no. 2, pp. 274-287. https://doi.org/10.7868/S0026898417020148

APA

Kulemzin, S. V., Kuznetsova, V. V., Mamonkin, M., Taranin, A. V., & Gorchakov, A. A. (2017). CAR T-cell therapy: Balance of efficacy and safety. Molekuliarnaia biologiia, 51(2), 274-287. https://doi.org/10.7868/S0026898417020148

Vancouver

Kulemzin SV, Kuznetsova VV, Mamonkin M, Taranin AV, Gorchakov AA. CAR T-cell therapy: Balance of efficacy and safety. Molekuliarnaia biologiia. 2017 May 26;51(2):274-287. doi: 10.7868/S0026898417020148

Author

Kulemzin, S. V. ; Kuznetsova, V. V. ; Mamonkin, M. et al. / CAR T-cell therapy : Balance of efficacy and safety. In: Molekuliarnaia biologiia. 2017 ; Vol. 51, No. 2. pp. 274-287.

BibTeX

@article{5d11805a625a48088e475f5cd052c9f3,
title = "CAR T-cell therapy: Balance of efficacy and safety",
abstract = "Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.",
keywords = "adoptive immunotherapy, cancer, chimeric antigen receptor, T-cells, Animals, Hematologic Neoplasms/genetics, Humans, Immunotherapy/methods, Oncogene Proteins, Fusion/genetics, Receptors, Antigen, T-Cell/genetics, T-Lymphocytes/immunology",
author = "Kulemzin, {S. V.} and Kuznetsova, {V. V.} and M. Mamonkin and Taranin, {A. V.} and Gorchakov, {A. A.}",
year = "2017",
month = may,
day = "26",
doi = "10.7868/S0026898417020148",
language = "English",
volume = "51",
pages = "274--287",
journal = "Molekulyarnaya Biologiya",
issn = "0026-8984",
publisher = "Russian Academy of Sciences",
number = "2",

}

RIS

TY - JOUR

T1 - CAR T-cell therapy

T2 - Balance of efficacy and safety

AU - Kulemzin, S. V.

AU - Kuznetsova, V. V.

AU - Mamonkin, M.

AU - Taranin, A. V.

AU - Gorchakov, A. A.

PY - 2017/5/26

Y1 - 2017/5/26

N2 - Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.

AB - Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.

KW - adoptive immunotherapy

KW - cancer

KW - chimeric antigen receptor

KW - T-cells

KW - Animals

KW - Hematologic Neoplasms/genetics

KW - Humans

KW - Immunotherapy/methods

KW - Oncogene Proteins, Fusion/genetics

KW - Receptors, Antigen, T-Cell/genetics

KW - T-Lymphocytes/immunology

UR - http://www.scopus.com/inward/record.url?scp=85027534212&partnerID=8YFLogxK

U2 - 10.7868/S0026898417020148

DO - 10.7868/S0026898417020148

M3 - Review article

C2 - 28537234

AN - SCOPUS:85027534212

VL - 51

SP - 274

EP - 287

JO - Molekulyarnaya Biologiya

JF - Molekulyarnaya Biologiya

SN - 0026-8984

IS - 2

ER -

ID: 10064711